Ensemble Docking Approach to Mitigate Pregnane X Receptor-Mediated CYP3A4 Induction Risk

被引:0
|
作者
Chen, Qi [5 ]
Zhou, Xin [1 ]
Rehmel, Jessica [1 ]
Steele, James P. [2 ]
Svensson, Kjell A. [3 ]
Beck, James P. [4 ]
Hembre, Erik J. [5 ]
Hao, Junliang [4 ]
机构
[1] Eli Lilly & Co, Lilly Biotechnol Ctr, Drug Disposit, San Diego, CA 92121 USA
[2] Eli Lilly & Co, Lilly Biotechnol Ctr, Quantitat Biol, San Diego, CA 92121 USA
[3] Eli Lilly & Co, Lilly Biotechnol Ctr, Neurosci Discovery, San Diego, CA 92121 USA
[4] Eli Lilly & Co, Lilly Biotechnol Ctr, Discovery Chem Res & Technol, San Diego, CA 92121 USA
[5] Eli Lilly & Co, Lilly Res Labs, Discovery Chem Res & Technol, Indianapolis, IN 46285 USA
关键词
INHIBITORS OPTIMIZING POTENCY; SUBTYPE-SELECTIVE AGENTS; POTENTIAL THERAPEUTICS; COACTIVATOR BINDING; CRYSTAL-STRUCTURE; RECENT PROGRESS; PXR; DISCOVERY; COMPLEX; SULFONAMIDES;
D O I
10.1021/acs.jcim.2c01175
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Three structurally closely related dopamine D1 receptor positive allosteric modulators (D1 PAMs) based on a tetrahydroisoquinoline (THIQ) scaffold were profiled for their CYP3A4 induction potentials. It was found that the length of the linker at the C5 position greatly affected the potentials of these D1 PAMs as CYP3A4 inducers, and the level of induction correlated well with the activation of the pregnane X receptor (PXR). Based on the published PXR X-ray crystal structures, we built a binding model specifically for these THIQ-scaffold-based D1 PAMs in the PXR ligand-binding pocket via an ensemble docking approach and found the model could explain the observed CYP induction disparity. Combined with our previously reported D1 receptor homology model, which identified the C5 position as pointing toward the solvent-exposed space, our PXR-binding model coincidentally suggested that structural modifications at the C5 position could productively modulate the CYP induction potential while maintaining the D1 PAM potency of these THIQ-based PAMs.
引用
收藏
页码:173 / 186
页数:14
相关论文
共 50 条
  • [41] Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4
    Hustert, E
    Zibat, A
    Presecan-Siedel, E
    Eiselt, R
    Mueller, R
    Fuss, C
    Brehm, I
    Brinkmann, U
    Eichelbaum, M
    Wojnowski, L
    Burk, O
    DRUG METABOLISM AND DISPOSITION, 2001, 29 (11) : 1454 - 1459
  • [42] CYP3A4 Induction in the Liver and Intestine of Pregnane X Receptor/CYP3A-Humanized Mice: Approaches by Mass Spectrometry Imaging and Portal Blood Analysis
    Kobayashi, Kaoru
    Kuze, Jiro
    Abe, Satoshi
    Takehara, Shoko
    Minegishi, Genki
    Igarashi, Katsuhide
    Kitajima, Satoshi
    Kanno, Jun
    Yamamoto, Takushi
    Oshimura, Mitsuo
    Kazuki, Yasuhiro
    MOLECULAR PHARMACOLOGY, 2019, 96 (05) : 600 - 608
  • [43] Different Inductive Effects of Praziquantel Racemate and its Enantiomers on the Enzyme CYP3A4 Mediated by Pregnane X Receptor and its Variants
    Meng, Ran
    Zhang, Xueli
    Wang, Haina
    Zhang, Danlu
    Zhao, Xin
    CURRENT DRUG METABOLISM, 2021, 22 (03) : 232 - 239
  • [44] Pregnane X receptor polymorphism affects CYP3A4 induction via a ligand-dependent interaction with steroid receptor coactivator-1
    Lim, Yun-Ping
    Huang, Jin-Ding
    PHARMACOGENETICS AND GENOMICS, 2007, 17 (05): : 369 - 382
  • [45] Triptolide and atorvastatin synergistically promote hepatotoxicity in cultured hepatocytes and female Sprague-Dawley rats by inhibiting pregnane X receptor-mediated transcriptional activation of CYP3A4
    Zheng, Nan
    Wei, Aili
    Wu, Tong
    Long, Long
    Yang, Haiying
    Li, Hua
    Wang, Lili
    TOXICOLOGY LETTERS, 2021, 342 : 85 - 94
  • [46] Role of human pregnane X receptor in tamoxifen-and 4-hydroxytamoxifen-mediated CYP3A4 induction in primary human hepatocytes and LS174T cells
    Sane, Rucha S.
    Buckley, Donna J.
    Buckley, Arthur R.
    Nallani, Srikanth C.
    Desai, Pankaj B.
    DRUG METABOLISM AND DISPOSITION, 2008, 36 (05) : 946 - 954
  • [47] Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor
    Faucette, Stephanie R.
    Sueyoshi, Tatsuya
    Smith, Cornelia M.
    Negishi, Masahiko
    LeCluyse, Edward L.
    Wang, Hongbing
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 317 (03): : 1200 - 1209
  • [48] Polycyclic Aromatic Hydrocarbons Activate CYP3A4 Gene Transcription through Human Pregnane X Receptor
    Kumagai, Takeshi
    Suzuki, Hiroyuki
    Sasaki, Takamitsu
    Sakaguchi, Shuhei
    Miyairi, Shinichi
    Yamazoe, Yasushi
    Nagata, Kiyoshi
    DRUG METABOLISM AND PHARMACOKINETICS, 2012, 27 (02) : 200 - 206
  • [49] Regulation of CYP3A4 by pregnane X receptor: The role of nuclear receptors competing for response element binding
    Istrate, Monica A.
    Nussler, Andreas K.
    Eichelbaum, Michel
    Burk, Oliver
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 393 (04) : 688 - 693
  • [50] Pregnane X receptor (PXR) polymorphism affects CYP3A4 induction via a ligand-dependent interaction with SRC-1
    Lim, Yun-Ping
    Huang, Jin-ding
    Huang, Jin-ding
    DRUG METABOLISM REVIEWS, 2006, 38 : 116 - 117